Literature DB >> 10516068

A lentivirus packaging system based on alternative RNA transport mechanisms to express helper and gene transfer vector RNAs and its use to study the requirement of accessory proteins for particle formation and gene delivery.

N Srinivasakumar1, F G Schuening.   

Abstract

A lentivirus-based packaging system was designed to reduce the chance of recombination between helper and gene transfer vector sequences by using the constitutive transport element (CTE) derived from Mason-Pfizer monkey virus for expression of the viral proteins and the Rev-Rev response element (RRE) combination for expression of the gene transfer vector. Using this approach, we evaluated a series of human immunodeficiency virus type 1 packaging constructs that express one or more accessory proteins (Vif, Vpr, and Vpu), in addition to the Gag and Pol proteins, for particle formation and virus stock production for gene transfer. Constructs that also express Vpr or both Vpr and Vpu produced more particles, as measured by a p24 assay, than did plasmids that did not contain these sequences. Transactivation experiments showed that the packaging plasmids that encode Vpr or both Vpr and Vpu also expressed a functional single-exon Tat protein. For these constructs, high-titer virus stocks could be prepared in the absence of a cotransfected Tat-expressing plasmid. Amphotropic-envelope-pseudotyped virus stocks prepared with all of the packaging constructs, irrespective of whether any of the accessory proteins were coexpressed, were equally efficient in transducing growth-arrested HeLa cells. The combination/mixed packaging system was compared to systems that were based on either the CTE alone or Rev and RRE for expression of both the packaging plasmid as well as the gene transfer vector. The combination/mixed packaging system was comparable to the other systems for production of virus stocks, suggesting that this design may prove to be safer for the eventual deployment of lentivirus vectors for therapeutic purposes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10516068      PMCID: PMC112994     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A.

Authors:  C Aiken
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines.

Authors:  N Srinivasakumar; N Chazal; C Helga-Maria; S Prasad; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  Tat is required for efficient HIV-1 reverse transcription.

Authors:  D Harrich; C Ulich; L F García-Martínez; R B Gaynor
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

4.  Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway.

Authors:  M Ott; S Emiliani; C Van Lint; G Herbein; J Lovett; N Chirmule; T McCloskey; S Pahwa; E Verdin
Journal:  Science       Date:  1997-03-07       Impact factor: 47.728

5.  Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors.

Authors:  T Kafri; U Blömer; D A Peterson; F H Gage; I M Verma
Journal:  Nat Genet       Date:  1997-11       Impact factor: 38.330

6.  HIV-1 particle release mediated by Vpu is distinct from that mediated by p6.

Authors:  M D Schwartz; R J Geraghty; A T Panganiban
Journal:  Virology       Date:  1996-10-01       Impact factor: 3.616

7.  Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector.

Authors:  H Miyoshi; M Takahashi; F H Gage; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

8.  Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo.

Authors:  R Zufferey; D Nagy; R J Mandel; L Naldini; D Trono
Journal:  Nat Biotechnol       Date:  1997-09       Impact factor: 54.908

9.  The human immunodeficiency virus type 1 encapsidation site is a multipartite RNA element composed of functional hairpin structures.

Authors:  M S McBride; A T Panganiban
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

10.  The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses.

Authors:  R K Naviaux; E Costanzi; M Haas; I M Verma
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

View more
  10 in total

1.  Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.

Authors:  M R Mautino; N Keiser; R A Morgan
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Replication-competent lentivirus analysis of clinical grade vector products.

Authors:  Kenneth Cornetta; Jing Yao; Aparna Jasti; Sue Koop; Makhaila Douglas; David Hsu; Larry A Couture; Troy Hawkins; Lisa Duffy
Journal:  Mol Ther       Date:  2010-12-21       Impact factor: 11.454

3.  Transfection of nerve cells.

Authors:  S V Salozhin; A P Bol'shakov
Journal:  Neurosci Behav Physiol       Date:  2010-02-10

4.  Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products.

Authors:  Kenneth Cornetta; Lisa Duffy; Cameron J Turtle; Michael Jensen; Stephen Forman; Gwendolyn Binder-Scholl; Terry Fry; Anne Chew; David G Maloney; Carl H June
Journal:  Mol Ther       Date:  2017-09-12       Impact factor: 11.454

5.  Novel Tat-encoding bicistronic human immunodeficiency virus type 1-based gene transfer vectors for high-level transgene expression.

Authors:  N Srinivasakumar; F Schuening
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

6.  Evaluation of Tat-encoding bicistronic human immunodeficiency virus type 1 gene transfer vectors in primary canine bone marrow mononuclear cells.

Authors:  Narasimhachar Srinivasakumar; Michail Zaboikin; Tatiana Zaboikina; Friedrich Schuening
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

7.  Rev-free HIV-1 gene delivery system for targeting Rev-RRE-Crm1 nucleocytoplasmic RNA transport pathway.

Authors:  Narasimhachar Srinivasakumar
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

8.  Lentiviral-mediated gene correction of mucopolysaccharidosis type IIIA.

Authors:  Donald S Anson; Chantelle McIntyre; Belinda Thomas; Rachel Koldej; Enzo Ranieri; Ainslie Roberts; Peter R Clements; Kylie Dunning; Sharon Byers
Journal:  Genet Vaccines Ther       Date:  2007-01-16

9.  RRE-deleting self-inactivating and self-activating HIV-1 vectors for improved safety.

Authors:  Narasimhachar Srinivasakumar
Journal:  PeerJ       Date:  2013-06-04       Impact factor: 2.984

10.  Substitution of the Rev-response element in an HIV-1-based gene delivery system with that of SIVmac239 allows efficient delivery of Rev M10 into T-lymphocytes.

Authors:  Narasimhachar Srinivasakumar
Journal:  AIDS Res Ther       Date:  2008-06-05       Impact factor: 2.250

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.